BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Day In Review: VaxGen, Inc. (VXGN) Pays $104 Million For Cabrellis Pharmaceuticals Corporation


11/16/2006 7:31:27 PM

November 16, 2006 -- Pharmion bought privately held Cabrellis and its cancer drug for a price of up to $104 million; Advinus partnered up with Merck to discover metabolic disorder drugs; VaxGen received a one-month extension to resolve the clinical hold on its anthrax vaccine; Dendreon placed 9.9 million shares, raising $45 million; Genzyme said Renagel improved outcomes in dialysis patients; CuraGen and TopoTarget began another trial of PXD101, this time for myelodysplastic syndromes; and Oscient implemented a 1-for-8 reverse split. The Centient Biotech 200™ rose 12 points to 3983, a gain of .31%. More details...

Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES